Dormant
RGEN · Repligen Corporation
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on the last session; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Repligen's bioprocessing recovery and BioLife deal support a breakout thesis above the $182.03 market high. BioLife approval on 2026-10-05 and a weekly close above that high would confirm the next leg; a weekly close below $158 would invalidate it.
Kill line
A weekly close below $158 invalidates the recovery structure, losing the early-August support area marked by the 2026-08-05 adjusted close of $158.59.
Pick status
Open commitment catalyst in 15dscored if the kill line above fires How this is scored →Latest analysis and events for RGEN —
As of 20 September 2026, the latest FrontierPicks analysis for Repligen Corporation (RGEN): Repligen's bioprocessing recovery and BioLife deal support a breakout thesis above the $182.03 market high. BioLife approval on 2026-10-05 and a weekly close above that high would confirm the next leg; a weekly close below $158 would invalidate it.
Kill line: A weekly close below $158 invalidates the recovery structure, losing the early-August support area marked by the 2026-08-05 adjusted close of $158.59.
Next dated event on file: — catalyst in 15d.
Current Thesis
Repligen's bioprocessing recovery thesis now requires BioLife merger approval on 2026-10-05 and a weekly close above the $182.03 market high to confirm another leg; a weekly close below $158 invalidates that price thesis. The operating evidence remains the 2026-07-28 guidance increase to fiscal 2026 revenue of $813–835 million, reported in the results release summarized by Benzinga.
The September refresh improves the case without establishing a breakout. The supplied adjusted close reached $176.89 on 2026-09-18, versus $167.60 on 2026-09-04. UBS raised its analyst price target from $195 to $225 on 2026-09-09, according to Benzinga's ratings record; the earlier concern that no target exceeded Wells Fargo's $185 has been overtaken by that publication.
The life-cycle assessment remains an inference: the narrative is maturing — the 2026-07-28 operating recovery story received fresh analyst support on 2026-09-09, but the 2026-09-18 close remained below the supplied $182.03 high. One target revision and selected closing prices do not establish expanding participation.
Bullish and bearish views on Repligen Corporation
The model's bull view on Repligen Corporation (RGEN), in brief: Operating results support recovery. Repligen's 2026-07-28 results, as reported by Benzinga, showed second-quarter revenue of $204.128 million against consensus of $201.483 million and adjusted earnings per share of $0.54 against $0.45. Management raised fiscal 2026 revenue… The bear view: Reported profitability remains weaker. The 2026-07-28 second-quarter filing figures summarized by Simply Wall St showed net income of $5.01 million against $14.87 million a year earlier. The adjusted headline does not resolve that deterioration. The price already reflects… Both cases follow in full.
Bull Case
- Operating results support recovery. Repligen's 2026-07-28 results, as reported by Benzinga, showed second-quarter revenue of $204.128 million against consensus of $201.483 million and adjusted earnings per share of $0.54 against $0.45. Management raised fiscal 2026 revenue guidance to $813–835 million from $803–833 million.
- An antitrust condition has cleared. Repligen's September filing states that the Hart–Scott–Rodino antitrust waiting period expired on 2026-09-03. This removes that closing condition, while shareholder approval and other conditions remain outstanding. Repligen Form 8-K
- Analyst support has strengthened. UBS's 2026-09-09 target increase to $225 supplies a concrete change since the previous note. It is an analyst forecast, not evidence that Repligen has delivered additional revenue. Benzinga ratings record
Bear Case
- Reported profitability remains weaker. The 2026-07-28 second-quarter filing figures summarized by Simply Wall St showed net income of $5.01 million against $14.87 million a year earlier. The adjusted headline does not resolve that deterioration.
- The price already reflects recovery. The supplied adjusted series shows a three-month gain of 39.8% through 2026-09-18, with the close still 2.8% below the $182.03 high. That combination documents appreciation without a confirmed break through the high.
- Acquisition consideration includes new equity. The 2026-09-04 prospectus specifies $11.25 cash plus 0.1442 Repligen shares per BioLife share, subject to the agreement's terms. Potential issuance is observable; actual merger-related short selling is not established by those terms. Merger prospectus
Setup & Price Structure
The 2026-09-18 adjusted close of $176.89 sits above the 2026-08-28 close of $176.27 and the 2026-09-04 close of $167.60. The supplied 14-day relative strength index (RSI) was 50.7 on 2026-09-18. These are measured observations; they do not establish trading-volume breadth, institutional accumulation or retail crowding. Moving-average and current short-interest measurements are unavailable in the evidence reviewed.
The $182.03 high in the 2026-09-18 price record defines the proposed breakout test. The retained research invalidation is a weekly close below $158, referencing the early-August area marked by the supplied 2026-08-05 close of $158.59. The limited observations support a recovery in price, but no conclusion about how widely that recovery is supported.
Catalyst Calendar (next 30 days)
- 2026-10-05 — BioLife shareholder meeting. The virtual meeting is scheduled for 9:00 a.m. Eastern Time to consider the merger agreement. Approval would satisfy the shareholder condition; it would not itself establish completion or the issuance date. 2026-09-04 merger prospectus
The 2026-09-09 Wells Fargo conference has passed and appears as a recent event on Repligen's investor-relations page. No confirmed third-quarter reporting date was established in the material reviewed as of 2026-09-20, so the earlier estimated date is not retained.
What Would Change Our Mind
Loss of the early-August price support would break the recovery structure: a weekly close below $158 is the explicit invalidation condition, anchored to the 2026-08-05 close of $158.59. Conversely, BioLife approval on 2026-10-05 together with a weekly close above the $182.03 high would meet the published confirmation test.
A reduction to the $813–835 million fiscal 2026 revenue range announced on 2026-07-28 would undermine the operating argument independently of the chart. A rejected merger proposal on 2026-10-05 would remove the acquisition leg; an adjournment would leave that leg unresolved.
Correlation Notes
This remains a single-name assessment: the 2026-09-18 price record contains no matched peer-return series sufficient to establish a bioprocessing group move or a correlation coefficient. The bioprocessing and cell-therapy tags describe business exposure, not measured market correlation.
The 2026-09-04 merger prospectus establishes a contractual link between BioLife's proposed consideration and Repligen's share price through the 0.1442 exchange ratio. It does not establish the amount or direction of arbitrage hedging in Repligen. Merger prospectus
Notes
- Adjusted EPS excludes intangible amortization and deal items; Q2 2026 GAAP diluted EPS from continuing operations was $0.09 against the $0.54 adjusted headline.
- Q3 2026 report date is not confirmed by the company as of 2026-09-06; the late-October reference is an estimate from prior reporting cadence.
- Institutional ownership was reported at 97.64% in a mid-August aggregation, so retail-sentiment coverage is a weak signal for this name.
- BioLife merger consideration uses a fixed 0.1442 Repligen share ratio, so the deal's value to BioLife holders moves one-for-one with Repligen's price.
- The preliminary S-4 describes a 19.9% share-issuance cap that can shift part of the merger consideration from stock to cash.
Related · shared themes
CYRX
CryoPort, Inc.
Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability crossover; the stock closed $15.12 on 2026-08-07, 8.8% under the $16.57 high, with no scheduled catalyst until ~November.
MGTX
MeiraGTx Holdings plc
The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but the next hard clinical binary (AQUAx2) is a year out in Q2 2027.
AGIO
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals' mitapivat label-expansion thesis turns on FDA approval for sickle cell disease by 2026-11-01. Approval would validate the regulatory case; a weekly close below $29 would invalidate the price structure first.
BOLD
Boundless Bio, Inc.
Boundless Bio’s merger thesis pairs a planned $44–48 million cash distribution with a minority Serapha interest. Completion by 2026-12-31 with that distribution intact would confirm the case; a weekly close below $2.40 would invalidate its market structure first.